Clinical Trial Update: Adjuvant TACE in HCC With High-risk Recurrence Factors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant transarterial chemoembolization to reduce recurrence risk in hepatocellular carcinoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Guangxi Medical University | Conditions: Hepatocellular Carcinoma, Adjuvant | Phase 3 | Status: RECRUITING